AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
edatrexate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| folic acid analogues | 986 | 80576-83-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 4.23 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,ITK,MAP3K21,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PIK3CD,PRKDC,SIK2,STK33,SYK,TEK | 28 | |||
| kinase-selectivity-class | EIF2AK3,GRK2,MAPK7 | 3 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 0.594 | Moderate | 0.69 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 0 | Moderate | 0.69 | |
| rat-kpuu-brain | Rat brain Kpuu | 0.006 | % | Moderate | 0.69 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 1, 1978 | YEAR INTRODUCED |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D005493 | Folic Acid Antagonists |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.61 | acidic |
| pKa2 | 5.3 | acidic |
| pKa3 | 13.13 | acidic |
| pKa4 | 4.62 | Basic |
| pKa5 | 4.51 | Basic |
| pKa6 | 1.39 | Basic |
| pKa7 | 0.25 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Dihydrofolate reductase | Enzyme | INHIBITOR | IC50 | 8.36 | WOMBAT-PK | KEGG DRUG | |||
| Folylpolyglutamate synthase, mitochondrial | Enzyme | WOMBAT-PK | |||||||
| Dihydrofolate reductase | Enzyme | Ki | 6 | CHEMBL | |||||
| Dihydrofolate reductase | Enzyme | IC50 | 8.42 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D03942 | KEGG_DRUG |
| C0044667 | UMLSCUI |
| CHEBI:135757 | CHEBI |
| CHEMBL296373 | ChEMBL_ID |
| C040210 | MESH_SUPPLEMENTAL_RECORD_UI |
| 6471 | INN_ID |
| JT4X6Z1HRR | UNII |
| 6917908 | PUBCHEM_CID |
| JT4X6Z1HRR | INXIGHT DRUGS |
Pharmaceutical products:
None